Use of ErbB-1 and ErbB-2 to select endocrine therapy for breast cancer: Will it play in peoria?

Journal of Clinical Oncology

Volumn 19, Issue 18, 2001, Pages 3795-3797

  Pritchard, K I ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; FADROZOLE; LETROZOLE; MEGESTROL ACETATE; ONCOPROTEIN; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SURGERY; CLINICAL TRIAL; DRUG RESPONSE; EDITORIAL; HUMAN; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL;

EID: 0035884432     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.18.3795     Document Type: Editorial

References (15)

1. Letrozole is more effective neoadjuvant therapy than Tamoxifen for ErbB-1- and ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial
2. Prognostic and predictive factors in breast cancer by immunohistochemical analysis
3. Specificity of hercep test in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system
4. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of Herceptin (trastuzumab) therapy for breast cancer
5. 20 Year update of the naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erb-B2 expression and tamoxifen efficacy
6. 20th Annual San Antonio breast cancer symposium
7. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer
8. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
9. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein 386
10. C-erbB-2 is a marker of resistance to endocrine therapy in advanced breast cancer
11. erbB-2 and response to doxorubicin in patients with axillary lymph node positive, hormone receptor negative breast cancer
12. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A southwest Oncology Group study 385
13. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer
14. Serum HER-2/neu and response to megace vs an aromatase inhibitor
15. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the international letrozole breast cancer group